Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- GlaxoSmithKline Employees Fume Over Latest Round of Layoffs
- GlaxoSmithKline is historically terrible at handling layoffs news, and the round of job cuts that appears imminent is no exception. (Update: the official announcement is coming on Wednesday.) As usual, the news is being debated all over the net before management has gotten out of bed just like last time....
- Blog posts 2008-11-04
Additional Resources
- GSK's Troy Hobbled His Future Employer From Reporting Tykerb Risks
- It comes as no surprise that Daniel Troy, the current general counsel to GlaxoSmithKline, is at the center of the preemption mess unveiled by Rep. Henry Waxman today. It is surprising, however, that Troy's actions led to a three-month delay in getting a label change requested by GSK for Tykerb,...
- Blog posts 2008-10-29
- GSK's Troy Hobbled His Future Employer From Reporting Tykerb Risks
- GSK's Troy Hobbled His Future Employer From Reporting Tykerb RisksRE: GSK's Troy Hobbled His Future Employer From Reporting Tykerb RisksTo learn more about Preemption go to the site - http://pharmaccountability.org See what organizations listed below have to say about the current state of drug and device safety in the United...
- Discussion threads 2008-10-29
- FDA approve GSK breast cancer drug
- GlaxoSmithKline has received FDA approval for Tykerb lapatinib, in combination with Xeloda capecitabine, for the treatment of advanced or metastatic HER2 (ErbB2)-positive breast cancer in women whose disease has progressed despite treatment with priorGlaxoSmithKline has received FDA approval for Tykerb lapatinib, in combination with Xeloda capecitabine, for the treatment of...
- Research articles 2007-04-01
- UK Nixes GSK Cancer Drug; Politics of Pricing Revealed
- UK Nixes GSK Cancer Drug; Politics of Pricing RevealedRE: UK Nixes GSK Cancer Drug; Politics of Pricing RevealedFT is wrong and so are you. There is a pre-test for Tykerb to determine if a woman is one of the 25 percent who would respond. Further, there are gene profiling tests...
- Discussion threads 2008-10-15
- UK Nixes GSK Cancer Drug; Politics of Pricing Revealed
- The UK's drug pricing control board, NICE, which says yea or nay to drugs that the National Health Service can use, said Tuesday it would not approve Tyverb for use on British patients. The interim decision reveals how political the world of cancer has become, with science taking a back...
- Blog posts 2008-10-15
- Time to Buy ImmunoGen
- David Rau submits: With the overall stock market and the economy in shambles, is it time to start looking at beaten-down biotechs for large percentage moves. My choice for huge upside growth is ImmunoGen IMGN. As many know, Genentech DNA recently announced that trastuzumab-dm1 will enter a pivotal...
- External links 2008-12-04
- List of 56 Drugs That Should Not Be Mixed With Viagra Contains Some Surprises
- Public Citizen has published a list of 56 drugs that interact badly with erectile dysfunction pills such as Pfizer's Viagra. Public Citizen's WorstPills.com site reports: In combination with ED drugs, these 56 drugs can cause dangerous falls in blood pressure that could lead to a heart attack or stroke;...
- Blog posts 2009-01-06
- GSK, Again, Has a Legal Friend in Washington
- You could be forgiven for thinking that under the Obama Administration, GlaxoSmithKline might be at something of a disadvantage as a lobbyist. After all, GSK's general counsel is the ultra-conservative Daniel Troy pictured, the man who, when at the FDA under Bush, tried to write regulations that...
- Blog posts 2009-02-10
- Immunogen: Moving on Up
- David Rau submits: As evidenced by the volume of shares traded, [[IMGN]] still has not caught the fancy of investors or traders of substance. IMGN has moved up smartly from month ago lows of 4 dollars and is now trading in the $7 range. The volume remains around...
- External links 2009-03-27
- GSK steps along desired path of evolution
- Andrew Witty, chief executive of GlaxoSmithKline, said on Wednesday that the group's traditional core market of prescription medicines in developed countries may fall to just a quarter of total sales. He also said that further diversification would focus more on revenue growth than profit margins. Unveiling third-quarter results, Mr Witty,...
- News items 2009-10-28
- << Previous
- page 1 of 1
- Next >>
